查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405853

神经生物标记市场规模、份额、趋势分析报告：按应用、类型、最终用途、地区和细分市场预测，2024-2030 年

Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

神经生物标记物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球神经生物标记市场规模将达到187.5亿美元，2024年至2030年复合年增长率为12.89%。

增加神经生物标记研发资金以促进开发新药预计将推动市场成长。美国国家神经疾病和中风研究所为进行临床检验、分析检验和生物标记发现相关研究的研究人员提供资助机会，包括合作研究协议和开发津贴。

生物标记在治疗神经系统疾病的药物开发中发挥重要作用。近年来，神经系统疾病治疗方法的研发投入大幅增加。例如，2020 年 12 月，非营利研究基金会 Target ALS 宣布为专注于发现 ALS 新型生物标记的计划提供 1500 万美元的研究经费，并预测在此期间市场增长预计将加速。

随着Quanterix Simoa（单分子阵列）等技术先进产品的出现，这是一种具有高信噪比的数位化ELISA 测试。该技术可以帮助克服与神经系统疾病相关生物标记相关的血脑障壁问题。预计此类技术进步将推动市场成长。例如，2021 年 1 月，雅培宣布首次针对创伤性脑损伤（包括脑震盪）进行快速血液检测。此测试测量脑外伤后血液中发现的特定蛋白质，如果测试结果呈阴性，可用于排除电脑断层扫描的需要。

特别是在开发中国家，对此类诊断产品缺乏认识、高成本以及神经科的可用性有限或缺乏等因素阻碍了此类基于生物标记的诊断解决方案的采用，可能会产生影响。根据世界神经病学联合会对 63/84 个 WHO 成员国的调查，31/63 个国家的大多数神经科都在大城市。一名神经科为大约 6,240 至 4,750,000 人提供服务。

神经生物标记物市场报告亮点

  • 蛋白质体学在 2023 年占据最大的市场占有率，预计在预测期内将保持其主导地位。蛋白质体学对于准确诊断疾病的发病和进展至关重要，因为它们会仔细检测转译后修饰和蛋白质特征。
  • 由于患病率上升以及研发活动的活性化，帕金森氏症领域占据了最大的市场占有率。
  • 从最终用途来看，研究机构和其他领域主导了神经生物标记市场。研究机构合作开发治疗神经系统疾病的药物，使用生物标记来评估抗药性。
  • 由于美国和加拿大市场参与者的强大影响力以及政府对新型生物标记开发的资助不断增加，北美在市场上占据主导地位。
  • 由于日本和澳洲等已开发国家以及中国和印度等新兴经济体越来越多地采用技术先进的诊断产品，亚太地区将在预测期内继续成长，预计将显着成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章神经生物标记市场变数、趋势与范围

  • 神经生物标记市场预测
    • 母市场展望
  • 绘製普及和成长前景图
  • 管道分析
    • 阿兹海默症
    • 帕金森氏症
    • 多发性硬化症
    • 泛自闭症障碍
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 神经生物标记：市场分析工具
    • 产业分析-波特五力分析
    • PESTLE分析

第 4 章 神经生物标记市场：細項分析（按类型），2018-2030

  • 神经生物标记市场：类型变异分析
    • 基因组
    • 蛋白质体学
    • 代谢组学
    • 影像
    • 其他的

第 5 章 神经生物标记市场：細項分析（按应用），2018-2030

  • 神经生物标记市场：应用变化分析
    • 阿兹海默症
    • 帕金森氏症
    • 多发性硬化症
    • 泛自闭症障碍
    • 其他的

第 6 章 神经生物标记市场：細項分析，依最终用途，2018-2030

  • 神经生物标记市场：最终用途变异分析
    • 医院和医院实验室
    • 独立临床诊断中心
    • 调查组织等

第 7 章 神经生物标记市场：細項分析，按地区，2018-2030

  • 区域市场简介
  • 北美洲
    • 北美神经生物标记市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲神经生物标记市场，2018-2030
    • 英国
    • 德国
    • 西班牙
    • 法国
    • 义大利
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区神经生物标记市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
    • 澳洲
  • 拉丁美洲
    • 拉丁美洲神经生物标记市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 中东和非洲神经生物标记市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章神经生物标记市场：竞争分析

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合作
    • 资金筹措
  • 2022 年公司市场占有率分析
  • 公司简介
    • Abbott
    • Johnson &Johnson Services, Inc.
    • Bio-rad Laboratories, Inc.
    • Alseres Pharmaceuticals, Inc.
    • Banyan Biomarkers, Inc.
    • Rules-based Medicine
    • Thermo Fisher Scientific, Inc.
    • Diagenic Asa
    • Merck &Co., Inc.
    • Quanterix
Product Code: GVR-3-68038-823-7

Neurological Biomarkers Market Growth & Trends:

The global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.

Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.

Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.

Neurological Biomarkers Market Report Highlights:

  • In 2023, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
  • Parkinson's disease segment held the largest market share owing to rising incidence and increasing R&D activities.
  • Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
  • North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
  • Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Segment Definition
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 GVR's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Application And Type Snapshot
  • 2.3 End Use Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Neurological Biomarkers Market Variables, Trends, And Scope

  • 3.1 Neurological Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Pipeline Analysis
    • 3.3.1 Alzheimer's Disease
    • 3.3.2 Parkinson's Disease
    • 3.3.3 Multiple Sclerosis
    • 3.3.4 Autism Spectrum Disorder
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Increasing Prevalence Of Neurological Diseases
      • 3.4.1.2 Technological Advancements
      • 3.4.1.3 Increased Funding For R&d In Biomarkers
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 Lack Of Consumer Awareness
      • 3.4.2.2 Reimbursement Policies
  • 3.5 Neurological Biomarkers: Market Analysis Tools
    • 3.5.1 Industry Analysis - Porter's Five Forces
    • 3.5.2 Pestle Analysis

Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 Neurological Biomarkers Market: Type Movement Analysis
    • 4.1.1 Genomic
      • 4.1.1.1 Genomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.2 Proteomic
      • 4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.3 Metabolomic
      • 4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.5 Imaging
      • 4.1.5.1 Imaging Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.6 Others
      • 4.1.6.1 Other Neurological Biomarkers Market, 2018 - 2030 (USD Million)

Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 Neurological Biomarkers Market: Application Movement Analysis
    • 5.1.1 Alzheimer's Disease
      • 5.1.1.1 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
    • 5.1.2 Parkinson's Disease
      • 5.1.2.1 Parkinson's Disease Market, 2018 - 2030 (USD Million)
    • 5.1.3 Multiple Sclerosis
      • 5.1.3.1 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
    • 5.1.4 Autism Spectrum Disorder
      • 5.1.4.1 Autism Spectrum Disorder Market, 2018 - 2030 (USD Million)
    • 5.1.5 Others
      • 5.1.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End-use, 2018 - 2030 (USD Million)

  • 6.1 Neurological Biomarkers Market: End-use Movement Analysis
    • 6.1.1 Hospital & Hospital Laboratories
      • 6.1.1.1 Hospitals & Hospital Laboratories Market, 2018 - 2030 (USD Million)
    • 6.1.2 Independent Clinical Diagnostic Centers
      • 6.1.2.1 Independent Clinical Diagnostic Centers Market, 2018 - 2030 (USD Million)
    • 6.1.3 Research Organizations And Others
      • 6.1.3.1 Research Organizations And Others Market, 2018 - 2030 (USD Million)

Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2 UK
      • 7.3.2.1 UK Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-pacific Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.4.2 Key Country Dynamics
      • 7.5.4.3 Regulatory Framework
      • 7.5.4.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 UAE Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Neurological Biomarkers Market: Competitive Analysis

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New Product Launches
    • 8.2.2 Partnerships
    • 8.2.3 Acquisitions
    • 8.2.4 Collaborations
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 Abbott
      • 8.4.1.1 Company Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product Benchmarking
      • 8.4.1.4 Strategic Initiatives
    • 8.4.2 Johnson & Johnson Services, Inc.
      • 8.4.2.1 Company Overview
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product Benchmarking
      • 8.4.2.4 Strategic Initiatives
    • 8.4.3 Bio-rad Laboratories, Inc.
      • 8.4.3.1 Company Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product Benchmarking
      • 8.4.3.4 Strategic Initiatives
    • 8.4.4 Alseres Pharmaceuticals, Inc.
      • 8.4.4.1 Company Overview
      • 8.4.4.2 Product Benchmarking
    • 8.4.5 Banyan Biomarkers, Inc.
      • 8.4.5.1 Company Overview
      • 8.4.5.2 Product Benchmarking
      • 8.4.5.3 Strategic Initiatives
    • 8.4.6 Rules-based Medicine
      • 8.4.6.1 Company Overview
      • 8.4.6.2 Financial Performance
      • 8.4.6.3 Product Benchmarking
      • 8.4.6.4 Strategic Initiatives
    • 8.4.7 Thermo Fisher Scientific, Inc.
      • 8.4.7.1 Company Overview
      • 8.4.7.2 Financial Performance
      • 8.4.7.3 Product Benchmarking
      • 8.4.7.4 Strategic Initiatives
    • 8.4.8 Diagenic Asa
      • 8.4.8.1 Company Overview
      • 8.4.8.2 Product Benchmarking
    • 8.4.9 Merck & Co., Inc.
      • 8.4.9.1 Company Overview
      • 8.4.9.2 Financial Performance
      • 8.4.9.3 Product Benchmarking
      • 8.4.9.4 Strategic Initiatives
    • 8.4.10 Quanterix
      • 8.4.10.1 Company Overview
      • 8.4.10.2 Product Benchmarking
      • 8.4.10.3 Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 3 North America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 Canada neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Europe neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 U.K. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.K. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 16 U.K. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 Germany neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 19 Germany neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 France neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 France neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 France neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Italy neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 24 Italy neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 25 Italy neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Spain neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 27 Spain neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 28 Spain neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Denmark neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 31 Denmark neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Sweden neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 33 Sweden neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 34 Sweden neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 Norway neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Norway neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 37 Norway neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Japan neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 42 Japan neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 43 Japan neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 China neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 45 China neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 46 China neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 India neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 48 India neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 49 India neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 South Korea neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 52 South Korea neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Australia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 54 Australia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 55 Australia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Thailand neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 57 Thailand neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 58 Thailand neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Latin America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 60 Latin America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 61 Latin America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Brazil neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 63 Brazil neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 64 Brazil neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Mexico neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 66 Mexico neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 67 Mexico neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 68 Argentina neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 69 Argentina neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 70 Argentina neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 MEA neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 72 MEA neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 73 MEA neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 South Africa neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Africa neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 76 South Africa neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 77 Saudi Arabia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 80 UAE neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 UAE neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 82 UAE neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 83 Kuwait neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 Kuwait neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 Kuwait neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Neurological biomarkers market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (Type and application)
  • Fig. 11 Segment snapshot (End-use)
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Biomarkers market value, 2023 (USD Million)
  • Fig. 14 Neurological biomarkers market dynamics
  • Fig. 15 Prevalence of Alzheimer's disease by age group, 2023
  • Fig. 16 Neurological biomarkers market: Porter's Five Forces analysis
  • Fig. 17 Neurological biomarkers market: PESTLE analysis
  • Fig. 18 Neurological biomarkers market: Type outlook and key takeaways
  • Fig. 19 Neurological biomarkers market: Type movement analysis
  • Fig. 20 Genomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Proteomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Metabolomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Imaging market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Other neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Neurological biomarkers market: Application outlook and key takeaways
  • Fig. 26 Neurological biomarkers market: Application movement analysis
  • Fig. 27 Alzheimer's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Autism spectrum disorder market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Neurological biomarkers market: End-use outlook and key takeaways
  • Fig. 33 Neurological biomarkers market: End-use movement analysis
  • Fig. 34 Hospitals & hospital laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Independent clinical diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Research organizations and others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Neurological biomarkers market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 U.S. neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Target disease prevalence
  • Fig. 43 Key country dynamics
  • Fig. 44 Canada neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Target disease prevalence
  • Fig. 46 Europe neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Target disease prevalence
  • Fig. 52 Key country dynamics
  • Fig. 53 France neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Italy neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Spain neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Denmark neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Sweden neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Norway neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Target disease prevalence
  • Fig. 65 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Asia Pacific neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Japan neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Target disease prevalence
  • Fig. 70 Key country dynamics
  • Fig. 71 China neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 India neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Target disease prevalence
  • Fig. 75 Key country dynamics
  • Fig. 76 Australia neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Korea neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Rest of Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Brazil neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Mexico neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Argentina neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Rest of Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 South Africa neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Target disease prevalence
  • Fig. 94 Key country dynamics
  • Fig. 95 Saudi Arabia neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Target disease prevalence
  • Fig. 97 Key country dynamics
  • Fig. 98 UAE neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Target disease prevalence
  • Fig. 100 Key country dynamics
  • Fig. 101 Kuwait neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Target disease prevalence
  • Fig. 103 Key payors in Kuwait
  • Fig. 104 Rest of MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key company categorization
  • Fig. 106 Company market positioning
  • Fig. 107 Company market share analysis, 2023
  • Fig. 108 Strategic framework